Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

 

NEWSROOM

  • Sep 21

    Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
  • Sep 18

    Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO

EVENTS

Events
More events are coming soon.